A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease

Background: Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of conditions ranging from simple steatosis to steatohepatitis, advanced fibrosis, and end stage liver disease. Despite the high prevalence and severity of hepatic illness, NAFLD remains underdiagnosed, because of few symptoms, lack of accurate laboratory markers. Objective: To evaluate a biochemical score for diagnosing non-alcoholic steatohepatitis. Methods: An observational, cross sectional study was carried out for a period of two years in the Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. 43 patients of Non-alcoholic fatty liver disease (NAFLD) attending at department of Hepatology were selected and underwent for biochemical investigations and liver biopsy with NAFLD Activity Score (NAS). Results: A biochemical score (TAAG score) assigned 1 point for each parameter (fasting serum triglyceride >ULN, alanine aminotransferase >ULN, AST/ALT ratio (AAR) ≤1 and gamma-glutamyl transferase >ULN) was evaluated. TAAG score ≥3 was present in 32.5% of study population and 40% of NASH patients. It had a sensitivity of 40%, specificity 26% and AUROC 0.54. Conclusion: Biochemical scoring system comprising traditional biomarkers did not significantly predict NASH. Biopsy is the only way to estimate steatohepatitis and/or fibrosis. Bangladesh J Medicine July 2019; 30(2) : 58-62

Download Full-text

Generalizability of the Nonalcoholic Steatohepatitis Clinical Research Network Histologic Scoring System for Nonalcoholic Fatty Liver Disease

Journal of Clinical Gastroenterology ◽

10.1097/mcg.0b013e3181dd1348 ◽

2011 ◽

Vol 45 (1) ◽

pp. 55-58 ◽

Cited By ~ 63

Author(s):

Ravi Juluri ◽

Raj Vuppalanchi ◽

John Olson ◽

Aynur Ünalp ◽

Mark L. Van Natta ◽

...

Keyword(s):

Liver Disease ◽

Clinical Research ◽

Fatty Liver ◽

Nonalcoholic Fatty Liver Disease ◽

Nonalcoholic Steatohepatitis ◽

Scoring System ◽

Fatty Liver Disease ◽

Research Network ◽

Nonalcoholic Fatty Liver ◽

Clinical Research Network

Download Full-text

Performance of autotaxin as a serum marker for liver fibrosis

Annals of Clinical Biochemistry International Journal of Laboratory Medicine ◽

10.1177/0004563217741509 ◽

2017 ◽

Vol 55 (4) ◽

pp. 469-477 ◽

Cited By ~ 10

Author(s):

Hitoshi Ikeda ◽

Mariko Kobayashi ◽

Hiromitsu Kumada ◽

Kenichiro Enooku ◽

Kazuhiko Koike ◽

...

Keyword(s):

Hyaluronic Acid ◽

Liver Disease ◽

Liver Fibrosis ◽

Hepatitis B ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Type Iv Collagen ◽

Alcoholic Fatty Liver ◽

Type Iv ◽

Alcoholic Fatty Liver Disease

Background Because autotaxin reportedly has a better performance than hyaluronic acid as a marker for liver fibrosis for the prediction of cirrhosis caused by hepatitis C, we aimed to further evaluate the role of autotaxin in liver fibrosis of other aetiologies. Methods Autotaxin antigen was measured in serum samples from 108 patients with chronic hepatitis B and 128 patients with non-alcoholic fatty liver disease who had undergone a liver biopsy as well as healthy subjects and patients with chronic kidney disease, diabetes mellitus, rheumatoid arthritis and cardiac dysfunction. Results When evaluated using receiver operator characteristics curves, the performance of autotaxin for the prediction of significant fibrosis (F2–F4) in chronic hepatitis B patients was better than that of hyaluronic acid or type IV collagen 7S. In non-alcoholic fatty liver disease patients, however, the performance of autotaxin for the prediction of significant fibrosis was poorer than that of hyaluronic acid or type IV collagen 7S. The increase in the serum autotaxin concentrations was less notable than that of hyaluronic acid or type IV collagen in patients with chronic kidney disease, diabetes mellitus, rheumatoid arthritis or cardiac dysfunction. Food intake did not affect the serum autotaxin concentrations. Conclusions Autotaxin is useful as a serum marker for liver fibrosis caused by not only chronic viral hepatitis C but also by hepatitis B, although it was less useful in patients with non-alcoholic fatty liver disease. The increase in serum autotaxin concentrations is fairly specific for liver fibrosis, and the serum autotaxin concentrations can be analysed without consideration of food intake before blood collection.

Download Full-text